Medical Information Only. Consult your healthcare provider before considering clinical trial enrollment.
Non-Muscle Invasive Bladder Carcinoma: early-phase trial registry
4 of 4 indexed Non-Muscle Invasive Bladder Carcinoma trials are currently recruiting, with more weight in Phase 1-2.
Corpus placement: #4,115 of 28,707 conditions by registered trial count.
4 US clinical trials · 4 currently recruiting · #4,115 of 28,707 conditions by registered trial count
Non-Muscle Invasive Bladder Carcinoma: 4 US clinical trials tracked, 4 recruiting.
Non-Muscle Invasive Bladder Carcinoma is the subject of 4 registered US clinical trials on ClinicalTrials.gov, 4 of them currently open to new participants. 1 are in Phase 3-4 (later-stage) and 3 in Phase 1-2 (earlier-stage). The most active sponsor is Aura Biosciences, running 1 of these trials.
Enrollment posture brief
Registry condition non-muscle-invasive-bladder-carcinoma
OPEN 4 | RECR 100% | LATE 1 | EARLY 3 | RANK #4115 | SPON 1
Volume-matched condition peers
Nearest open-share peer: Aortic Arch Aneurysm (100% recruiting · 5 trials)
Non-Muscle Invasive Bladder Carcinoma lists 4 open slots (100% of 4 indexed trials). Peers are matched on registered volume, not therapeutic-area browse lists. How peer matching works →
Key findings
What ClinicalTrials.gov does not surface for Non-Muscle Invasive Bladder Carcinoma on its own pages , computed from the registry mirror as of 2026-08-08. Each line carries its own denominator so it can be quoted as it stands.
-
Non-Muscle Invasive Bladder Carcinoma is recruiting above its size-band peers.
4 of 4 indexed trials (100%) are open to enrollment, against a 46.5% average across 27,806 conditions with fewer than 20 trials. The peer set uses the same ClinicalTrials.gov-derived counts as this page.
Open and recent trials
4 total, page 1 of 1
A Cruciferous Vegetable Eating Program for the Reduction of Cancer Recurrence and Progression in Patients With Non-muscle Invasive Bladder Cancer
Roswell Park Cancer Institute
NCT06733363
A Phase 1, Open-label Trial of Belzupacap Sarotalocan (AU-011) in Bladder Cancer
Aura Biosciences
NCT05483868
In-home Intravesical Chemotherapy for the Treatment of Bladder Cancer, INVITE Trial
Mayo Clinic
NCT06704191
Studying the Relationship of Patient Positioning and Intravesical Bacillus Calmette Guerin Dwell Time to Improve the Treatment of Non-muscle Invasive Bladder Cancer
Ohio State University Comprehensive Cancer Center
NCT07474519
Phase Distribution
| Phase | Trial count |
|---|---|
| Phase 1 | 2 |
| Phase 2 | 1 |
| Phase 4 | 1 |
Top Sponsors
Named interventions
Most-linked intervention names on Non-Muscle Invasive Bladder Carcinoma records (sponsor-reported on ClinicalTrials.gov). Counts are trial links, not unique products.
US sites by state
Facility locations filed on Non-Muscle Invasive Bladder Carcinoma trials. A trial with sites in several states counts in each.
Source: ClinicalTrials.gov, National Library of Medicine. Data is informational only.
Related
What to do with this Non-Muscle Invasive Bladder Carcinoma page
4 registered trials, 4 currently recruiting, is a starting point for a conversation, not a diagnosis or a recommendation.
- 4 Non-Muscle Invasive Bladder Carcinoma trials are currently recruiting, check eligibility criteria before contacting a site. Browse recruiting trials
- Aura Biosciences sponsors the most Non-Muscle Invasive Bladder Carcinoma trials on record, review their full trial history before evaluating a specific study. See Aura Biosciences's trials
- Bring the specific trial ID (NCT number) to your own doctor before enrolling, this page is a directory, not medical guidance. Read the trial-finding guide
Trial and recruiting counts reflect ClinicalTrials.gov registry status as of the data vintage above; individual trial eligibility and enrollment status can change.
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This Non-Muscle Invasive Bladder Carcinoma condition card totals 4 registered trials; most-linked intervention BCG Solution; top US site state New York. See our editorial standards & corrections policy, the methodology behind these numbers, the data changelog, or report a data error.